Jul 29, 2025
Alkermes plc Reports Second Quarter 2025 Financial Results
Jul 21, 2025
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
Jul 15, 2025
Alkermes to Report Second Quarter Financial Results on July 29, 2025
Jun 02, 2025
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
May 29, 2025
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025
Apr 30, 2025
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
Apr 17, 2025
Alkermes to Report First Quarter Financial Results on May 1, 2025
Apr 02, 2025
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
Apr 01, 2025
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Mar 27, 2025
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
Feb 26, 2025
Alkermes to Participate in Upcoming Investor Conferences
Jan 02, 2025
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nov 25, 2024
Alkermes to Participate in Upcoming Investor Conferences
Nov 07, 2024
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
Oct 24, 2024
Alkermes plc Reports Third Quarter 2024 Financial Results
Oct 17, 2024
Alkermes to Report Third Quarter Financial Results on October 24, 2024
Sep 19, 2024
Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference
Sep 13, 2024
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program
Aug 28, 2024
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Jul 24, 2024
Alkermes plc Reports Second Quarter 2024 Financial Results